|
|
|
|
Efruxifermin significantly reduced proportion of participants with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study
|
|
|
American Association for the Study of Liver Diseases 75th Annual Liver Meeting, November 15-19, 2024, San Diego, California.
M. NOUREDDIN1, C. BEHLING2, P. BEDOSSA3, L. SHAO4, E. CHNG5, Y. CHOUDHURY5, D. TAI5, D. CHAN6, E. FONG6, B. DE TEMPLE6, M. MINERVA6, M. BURCH6, K.
BARRETT6, R. SHRINGARPURE6, E. J. TILLMAN6, T. ROLPH6, A. CHENG6, K. YALE6, S. A. HARRISON7
1. Houston Research Institute; Houston Methodist Hospital, Houston, TX, USA; 2. Department of Pathology, Sharp Memorial Hospital,
2. San Diego, CA, USA; 3. Liverpat, Paris, France; 3. Institute of Cellular Medicine, University of Newcastle, Newcastle upon Tyne, UK;
3. 4. Fortrea Inc, Raleigh, NC, USA; 5. HistoIndex Pte Ltd, Singapore, Singapore; 6. Akero Therapeutics, South San Francisco, CA, USA; 7. Pinnacle Clinical Research, San Antonio and Austin, TX, USA
|
|
|
|
|
|
|